Today: 3 May 2026
Browse Category

NASDAQ:MGRX 13 November 2025 - 23 February 2026

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals shares fell about 4% to 51 cents in premarket trading Monday, easing after a 49% surge Friday that followed news of strong early sales for its $99-a-month testosterone therapy. Trading volume Friday spiked to 349 million shares. The company remains below Nasdaq’s $1 minimum bid requirement and has until August 3, 2026, to regain compliance.
23 February 2026
·
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····

Stock Market Today

  • Is XPeng (XPEV) Share Price Overvalued After Recent Declines?
    May 2, 2026, 11:10 PM EDT. XPeng's stock price closed at $15.83, falling 5% in the last week and 19.9% over the past year, despite a 52.2% gain over three years. A Discounted Cash Flow (DCF) analysis estimates XPeng's intrinsic value at $7.63 per share, suggesting the stock may be overvalued by 107.6% relative to current prices. The company's Price to Sales (P/S) ratio stands at 1.35, reflecting mixed signals amid volatile earnings and growth outlook. With a valuation score of 2 out of 6, XPeng shows signs of being undervalued on some metrics but overvalued on others, leaving investors weighing whether sentiment or fundamentals are driving the market price.

Latest article

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
JPMorgan Chase’s New Filing Shows the $31.4 Billion Number Investors Are Watching

JPMorgan Chase’s New Filing Shows the $31.4 Billion Number Investors Are Watching

3 May 2026
JPMorgan Chase reported first-quarter net income of $16.5 billion, up 13% from a year earlier, with revenue rising 10% to $49.8 billion. The bank’s SEC filing showed a $31.4 billion credit-loss allowance and noninterest expense up 14% to $26.9 billion. Nonperforming assets rose 10% to $10 billion. Shares closed Friday at $312.47, valuing the bank at about $864.8 billion.
Go toTop